Military veterans and peptides — the unique considerations for service-connected conditions

Some of what you're carrying has VA documentation behind it. Some of it doesn't, because it wasn't the kind of thing that produced a clear diagnosis at the right moment, or because the system you came back to wasn't set up to capture the full picture of what service does over time. Either way, you're managing it. And you're increasingly part of a veteran population that is looking at the longevity and performance medicine conversation and asking an intelligent question: where does this fit with what I'm dealing with?

The answer is that it fits, with specificity and coordination, in a context that is different from the general wellness population and that deserves more granular clinical attention than it usually gets.

The physiological profile common in many combat veterans and heavy-deployment service members includes a pattern that is recognizable in the research literature even if it isn't always recognized in the clinical encounter: chronic low-grade systemic inflammation, HPA axis dysregulation from sustained high-stress operational periods, autonomic nervous system changes consistent with chronic hypervigilance, musculoskeletal injury burden that was often managed to functional standards during service but never fully rehabilitated, immune dysregulation, and in a subset of veterans — particularly those with blast exposure histories or other TBI mechanisms — neurological changes whose full scope took years to characterize.

The musculoskeletal burden is often the most immediate, visible, and undertreated dimension of veteran health. Years of heavy load carriage, high-impact training, operational injury cycles where full recovery was neither possible nor culturally supported, and often inadequate physical therapy access add up to a chronic joint and soft tissue picture that is genuinely different from the acute injury population. BPC-157 has been researched for its potential to support tissue repair in multiple contexts — tendon, ligament, joint, muscle, and gut tissue — with a mechanism that involves VEGF signaling, growth factor upregulation, and inflammatory modulation. The research is primarily animal-model and early clinical, and it is a compounded compound available outside conventional prescribing. But the biological rationale is directly relevant to the injury profile common in this population, and it is among the compounds most frequently explored in veteran communities for chronic musculoskeletal recovery. This is an area where research-supported conversations with a peptide-knowledgeable prescribing provider are worth having.

TB-500 — a synthetic fragment of thymosin beta-4 — has a similar profile in terms of tissue repair research and is often discussed alongside BPC-157 in the recovery and regenerative medicine context. The same research caveats apply: the evidence is early, the compound is compounded, and the clinical evidence base is developing rather than established. For veterans with chronic soft tissue and connective tissue injuries, the mechanism is plausible and the specialist conversation is appropriate.

The TBI dimension of veteran health is among the most consequential and, until relatively recently, among the most clinically underserved. Traumatic brain injury in veterans ranges from mild single-event concussions to cumulative blast exposure injuries that may not have produced single identifiable events but that produced documented changes in cognitive function, neurological organization, and psychiatric risk over time. The conventional treatment paradigm for TBI has historically been supportive and conservative; the evidence base for specific pharmacological interventions has been limited.

Cerebrolysin is a peptide-containing compound derived from porcine brain tissue that has been studied extensively in Eastern European and Russian clinical settings for TBI and stroke recovery. It is not FDA-approved in the United States for these indications, but it has a clinical research literature that includes randomized controlled trials in acute and subacute TBI and stroke, with evidence for neurological recovery support. It is available through compounding channels and has been explored in veteran communities specifically for TBI sequelae. The evidence base is stronger than for many compounds in the peptide space, though the research comes primarily from non-U.S. settings and the regulatory pathway in the United States is not established. This is a conversation for a neurologist or TBI specialist with familiarity with the international evidence base.

Cortexin is a related peptide mixture from the same Eastern European clinical tradition, also studied in neurological recovery contexts. Semax, a synthetic peptide based on ACTH, has been studied in Russian clinical settings for cognitive recovery after stroke and TBI and is explored for its neuroprotective and cognitive-support properties. The evidence base for these compounds comes primarily from Russian academic sources; the clinical standards of evidence and regulatory frameworks differ from FDA processes. For veterans exploring these compounds for TBI-related cognitive and neurological symptoms, the clinical conversation requires a specialist who can evaluate the available evidence critically and who understands the specific injury picture. VA neurology programs are variable in their awareness of these compounds; private TBI specialists or integrative neurologists may have more familiarity.

Selank occupies a different register. It is a synthetic heptapeptide studied for its anxiolytic and adaptogenic properties, with a mechanism thought to involve GABA modulation and interactions with brain-derived neurotrophic factor. Research has explored it in anxiety and stress-response contexts, and in veteran communities it has been discussed in the context of PTSD-associated anxiety. It is available through compounding channels, is not FDA-approved, and its primary evidence base is from Russian academic settings. For veterans managing PTSD-related anxiety, the conversation about Selank belongs in coordination with a mental health specialist — not as a replacement for evidence-based PTSD treatments (Prolonged Exposure, EMDR, and certain pharmacological approaches have the strongest evidence base for PTSD) but as a potential adjunct in a comprehensive program. The mental health specialist managing the PTSD treatment is the appropriate source for evaluating this conversation.

Thymosin Alpha-1 addresses the immune dimension that is measurably elevated in concern in veteran populations, particularly those with exposure histories that may have created chronic immune activation. Some veterans — particularly those with Gulf War illness presentations, certain burn-pit exposure histories, or deployments associated with environmental toxin exposure — have immune and inflammatory profiles that are genuinely unusual and that conventional medicine has struggled to address adequately. Thymosin Alpha-1 has been studied as an immune modulator in multiple clinical contexts, including infectious disease and oncology applications, with a mechanism involving T-cell and natural killer cell activity. The research rationale for its use in immune dysregulation contexts is more developed than for many peptides. For veterans with documented immune or inflammatory abnormalities, the conversation with an immunologist or integrative medicine specialist with knowledge of Thymosin Alpha-1 is worth pursuing.

The mitochondrial peptide conversation is directly relevant to the fatigue dimension of veteran health. The chronic fatigue seen in Gulf War illness, in some TBI populations, and in veterans with complex service-connected conditions has a mitochondrial component that has been identified in research — the cellular energy production machinery is functioning below optimal capacity in ways that manifest as the kind of fatigue that sleep alone doesn't fully resolve. NAD+ precursors and compounds like MOTS-c, researched for their roles in metabolic regulation and cellular energy, address this dimension. These are not established standards of care for any of these conditions specifically, but they are an area of active research interest and an appropriate topic for specialist-supervised evaluation.

The burn-pit and environmental exposure question is its own evolving domain. The PACT Act and the growing policy recognition of burn-pit and other exposure-related health consequences have opened VA compensation and clinical access in ways that didn't exist a few years ago. The research into what specific exposures do to the body — to the respiratory system, the immune system, the oncological risk profile, the inflammatory picture — is ongoing. Some veteran communities and some researchers have been exploring peptide approaches in this population specifically, but the evidence base is highly preliminary and the field is young. The appropriate position here is engagement with the developing research and coordination with VA specialists and exposure-focused clinicians rather than self-directed supplementation.

The VA system context shapes everything about how this conversation unfolds practically. For most veterans, the VA provides the primary care framework for service-connected conditions. The VA system is generally not prescribing compounded peptides. That means veterans who want to explore these compounds are doing so through private-pay medicine, through direct-to-consumer channels, or through private practice providers who may or may not have the full context of their VA care. This gap is clinically significant. The private prescriber adding a peptide protocol needs to know the VA medications, the service-connected diagnoses, the TBI status, the PTSD treatment plan, and the full clinical picture to make appropriate recommendations. And the VA provider managing service-connected conditions benefits from knowing what else the veteran is using. That coordination requires intentional effort from the veteran — bringing records and medication lists to both settings — but it is the basis of safe integrated care.

The mental health dimension cannot be treated as separate from the physical dimension in veteran health. PTSD and TBI frequently co-occur, and the neurological, endocrine, and immune changes associated with both create a physiological picture that intersects with every other element of health management. Any peptide approach in a veteran with significant PTSD or TBI history should be coordinated with the mental health and neurology specialists who are managing those conditions, not added as an independent layer.

What the veteran population represents, from a peptide medicine standpoint, is a group with unusually high and specific need — real inflammatory burden, real musculoskeletal injury history, real neurological consideration in many cases, real immune dysregulation in some — combined with a healthcare system that is often not well-organized to address that need with the full range of tools that exist. The result is that many veterans are researching and self-directing at a rate that exceeds the clinical support available to them. The peptide conversations happening in veteran communities online are sophisticated and often thoughtful. They also occur without the clinical context that makes individual risk-benefit evaluation meaningful.

The goal is to bring that sophistication inside a clinical relationship: urologic and TBI specialists who know the injury history, mental health specialists who know the PTSD picture, and a prescribing provider who has the full clinical record and can evaluate which peptide approaches are worth exploring, in what sequence, with what monitoring. That integrated care is the appropriate container for these decisions. The veteran deserves a clinical team that is as thorough and systematic about recovery as the service that created the need for it was about its mission. That team exists, it is accessible in some settings more than others, and building it is worth the effort.